The new meta-analysis in JACC: Cardiovascular Imaging confirms Cardiac magnetic resonance (CMR) imaging is an especially effective tool for evaluating patients with pulmonary arterial hypertension (PAH).
The researchers concluded that “CMR can predict clinical worsening, in addition to confirming its prognostic role, in a large cohort of patients with PAH.
"This study provides a strong rationale for considering CMR as a clinical trial endpoint.”
They added, too, that “our findings highlight the clinical utility of CMR imaging and support further evaluation of this modality as a clinically meaningful trial endpoint for the assessment of new therapies for PAH.”
Elsewhere in the news
- Cardiac MRI a ‘powerful’ tool for assessing, predicting pulmonary arterial hypertension, Cardiovascular Business
- PAH Outcomes: Is This Technology a Window?, MedPage Today
- Cardiac Magnetic Resonance Evaluation of Pulmonary Arterial Hypertension: Transforming From Supplementary to Primary Imaging Modality?, Science Direct
Article
Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis (JACC: Cardiovascular Imaging) S. Alabed, Y. Shahin, P. Garg, F. Alandejani, C. S. Johns, R. A. Lewis, R. Condliffe, J. M. Wild, D. G. Kiely, A. J. Swift
